ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
Phase 2 – studying effectiveness and dosage
Conditions:
Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
Sponsor: ETOP IBCSG Partners Foundation
trial.available_in:
БГ
Overview
Trial status: Authorised
Objective response rate (ORR) according to RECIST v1.1, Duration of response (DoR), Disease control rate (DCR), Progression-free survival (PFS) according to RECIST v1.1, Incidence, nature, and severity of adverse events according to CTCAE v5, except for CRS and ICANS, that are graded according to the ASTCT criteria and TLS that are graded according to the Cairo-Bishop classification
Overall survival rate at 12 months (12-month OS)
Description
Objective response rate (ORR) according to RECIST v1.1, Duration of response (DoR), Disease control rate (DCR), Progression-free survival (PFS) according to RECIST v1.1, Incidence, nature, and severity of adverse events according to CTCAE v5, except for CRS and ICANS, that are graded according to the ASTCT criteria and TLS that are graded according to the Cairo-Bishop classification
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 40 participants
БГ